New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - doxazosin mesilate 4.852mg equivalent to doxazosin 4 mg - tablet - 4 mg - active: doxazosin mesilate 4.852mg equivalent to doxazosin 4 mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate sodium starch glycolate

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - doxazosin mesilate 4.852mg equivalent to doxazosin 4 mg - tablet - 4 mg - active: doxazosin mesilate 4.852mg equivalent to doxazosin 4 mg excipient: lactose magnesium stearate microcrystalline cellulose sodium laurilsulfate sodium starch glycolate

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 1 mg - doxazosin tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerou

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - doxazosin mesilate 2.44mg equivalent to 2 mg doxazosin;   - tablet - 2 mg - active: doxazosin mesilate 2.44mg equivalent to 2 mg doxazosin   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - doxazosin is indicated for the treatment of hypertension and can be used as the initial agent to control pressure in the majority of patients. for patients who are not adequately controlled on a singel antihypertensive agent, doxazosin can be used in combination with another agent such as a thiazide diuretic, a beta-blocker, a calcium antagonist or an angiotensin-converting enzyme inhibitor.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - doxazosin mesilate 4.87mg equivalent to 4 mg doxazosin;   - tablet - 4 mg - active: doxazosin mesilate 4.87mg equivalent to 4 mg doxazosin   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - doxazosin is indicated for the treatment of hypertension and can be used as the initial agent to control pressure in the majority of patients. for patients who are not adequately controlled on a singel antihypertensive agent, doxazosin can be used in combination with another agent such as a thiazide diuretic, a beta-blocker, a calcium antagonist or an angiotensin-converting enzyme inhibitor.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 1 mg - doxazosin tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin monotherapy. doxazosin provides rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. sustained improvements with doxazosin were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. doxazosin tablets are also indicated for the treatment of hypertension. doxazosin may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibitors. doxazosin

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin mesylate 1 mg - doxazosin tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin monotherapy. doxazosin provides rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. sustained improvements with doxazosin were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. doxazosin tablets are also indicated for the treatment of hypertension. doxazosin may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibito

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 2 mg - doxazosin tablets are indicated for the treatment of the signs and symptoms of bph. doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerou

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin mesylate 4 mg - doxazosin tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin monotherapy. doxazosin provides rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. sustained improvements with doxazosin were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. doxazosin tablets are also indicated for the treatment of hypertension. doxazosin may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibitors. doxazosin

United States - English - NLM (National Library of Medicine)

rebel distributors corp - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 2 mg - doxazosin mesylate is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin mesylate may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin mesylate monotherapy. doxazosin mesylate provides rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. sustained improvements with doxazosin mesylate were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. doxazosin mesylate is also indicated for the treatment of hypertension. doxazosin mesylate may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angio